The 340B Rebate Pilot Is Back at Under 5.5% of Sales, Rebuilt to Survive the Court That Killed It
HRSA restarted the 340B rebate pilot at under 5.5% of sales, wrapped in 21 pages of answers to the court that vacated the first one.
United States
KKR’s 51.8% Premium for Integer Is Measured From Before the Company Said It Was for Sale
KKR’s 51.8% premium for Integer is struck to the day before Integer said it was for sale. The 28.8% is what a holder actually gained.
Indivior’s Holders Take 56.5% and $1 Billion, Supernus Takes the Name, the CEO and the Building
Indivior holders take 56.5% and a billion in cash. Supernus takes the name, the CEO and the building. Equals describes the board seats only.
Curium’s CVR Waterfall Says It Trusts DEFINITY, Is Betting on Neurology, and Doubts Prostate
Curium locked 89.5% of consideration in cash and hung the rest on prostate. The CVR waterfall is the buyer’s own forecast, published.
An FDA Panel Voted 9-3 Against Capricor on Cardiomyopathy and Never Voted on the Endpoint That Passed
The ballot was the outcome. A drug’s strongest dataset sitting off the voting question is not a footnote, it is the whole result.
Revtorpyk Got Its NCCN Category 1 Listing Two Months Before Celcuity Can Sell a Single Vial
The reimbursement case is being built before the product exists. Two gates remain, and a guideline solves neither.
Washington Removed the Cushion Under Part D, and Handed the Auditors an Algorithm
Washington ended the subsidy holding Part D premiums down, charged a record number of Medicaid fraud defendants, and put prosecutors’ analytics inside CMS.
J&J Won the Ruling on 22 July. Five Days Later It Agreed to Pay $5.5 Billion.
J&J agreed to pay $5.5 billion to resolve roughly 76,000 ovarian talc claims, five days after a court ruling that put plaintiffs in an untenable position.